Возможности применения аналогов гонадотропин-рилизинг гормона у девочек пубертатного возраста с онкологическими заболеваниями
https://doi.org/10.17650/2311-1267-2015-2-4-34-41
Аннотация
Об авторах
М. Б. Белогурова
ГБОУ ВПО «Санкт-Петербургский государственный педиатрический медицинский университет» Минздрава России;
СПб ГБУЗ «Городская клиническая больница № 31»
Россия
Россия
194100, Санкт-Петербург, ул. Литовская, 2;
197110, Санкт-Петербург, просп. Динамо, 3
Ю. В. Диникина
ГБОУ ВПО «Санкт-Петербургский государственный педиатрический медицинский университет» Минздрава России;
ФГБУ «Северо-Западный федеральный медицинский исследовательский центр им. В.А. Алмазова» Минздрава России
Россия
Россия
194100, Санкт-Петербург, ул. Литовская, 2;
197341, Санкт-Петербург, ул. Аккуратова, 2
А. С. Лисянская
ГБОУ ВПО «Первый Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова» Минздрава России
Россия
Россия
197022,
Санкт-Петербург, ул. Льва Толстого, 6–8
Н. И. Тапильская
ГБОУ ВПО «Санкт-Петербургский государственный педиатрический медицинский университет» Минздрава России
Россия
194100, Санкт-Петербург, ул. Литовская, 2
Россия
194100, Санкт-Петербург, ул. Литовская, 2
Г. Г. Радулеску
СПб ГБУЗ «Городская клиническая больница № 31»
Россия
Россия
197110, Санкт-Петербург, просп. Динамо, 3
Т. Д. Викторович
СПб ГБУЗ «Городская клиническая больница № 31»
Россия
Россия
197110, Санкт-Петербург, просп. Динамо, 3
Л. И. Шац
ГБОУ ВПО «Санкт-Петербургский государственный педиатрический медицинский университет» Минздрава России;
СПб ГБУЗ «Городская клиническая больница № 31»
Россия
Россия
194100, Санкт-Петербург, ул. Литовская, 2;
197110, Санкт-Петербург, просп. Динамо, 3
Э. Д. Чавпецова
СПб ГБУЗ «Городская клиническая больница № 31»
Россия
Россия
197110, Санкт-Петербург, просп. Динамо, 3
Список литературы
1. Brenner H., Coebergh J.W., Parkin D.M. et al. Up-to-date monitoring of childhood cancer long-term survival in Europe: Leukaemias and lymphomas. Ann Oncol 2007;18(9):1569–77.
2. Blumenfeld Z., von Wolff M. GnRHanalogues and oral contraceptives for fertility preservation in women during chemotherapy. Hum Reprod Update 2008;14(6):543–52.
3. Michaeli J., Weintraub M., Gross E. et al. Fertility preservation in girls. Obstet Gynecol Int 2012;2012:139193.
4. Del Mastro L., Ceppi M., Poggio F. et al. Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in cancer women: Systematic review and meta-analysis of randomized trials. Cancer Treat Rev 2014;40(5):675–83.
5. Белогурова М.Б. Диникина Ю.В., Тапильская Н.И. и др. Нарушение фертильности как осложнение лечения онкологических заболеваний в детском и подростковом возрасте (обзор литературы). Евразийский онкологический журнал 2014;1:77–86. [Belogurova М.B., Dinikina Yu.V., Tapilskaya N.I. Violation of fertility as a complication of cancer treatment in children and adolescents (review). Yevraziyskiy onkologicheskiy zhurnal = Eurasian Journal of Oncology 2014;1:77–86. (In Russ.)].
6. Brown J., Demetri G. Challenges in the development of platelet growth factors: low expectations for low counts. Curr Hematol Rep 2002;1(2):110–8.
7. Meirow D., Rabinovici J., Katz D. et al. Prevention of severe menorrhagia in oncology patients with treatment-induced thrombocytopenia by luteinizing hormonereleasing hormone agonist and depomedroxyprogesterone acetate. Cancer 2006;107(7):1634–41.
8. Committee opinion no. 606: Options for prevention and management of heavy menstrual bleeding in adolescent patients undergoing cancer treatment. Obstet Gynecol 2014;124(2 Pt 1):397–402.
9. Hanker J.P. Gastrointestinal disease and oral contraception. Am J Obstet Gynecol 1990;163(6 Pt 2):2204–7.
10. Bates J.S., Buie L.W., Woodis C.B. Management of menorrhagia associated with chemotherapy-induced thrombocytopenia in women with hematologic malignancy. Pharmacotherapy 2011;31(11):1092–110.
11. Kline R., Fennewald L., Vore M. et al. Oral contraceptives a cause of hyperbilirubinemia in stem cell transplant patients. J Pediatr Hematol Oncol 1999;21(5):436–40.
12. Quaas A.M., Ginsburg E.S. Prevention and treatment of uterine bleeding in hematologic malignancy. Eur J Obstet Gynecol Reprod Biol 2007;134(1):3–8.
13. Loren A.S., Mangu P.B., Beck L.N. et al. Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2013;31(19):2500–10.
14. Patridge A.H., Gelber S., Peppercorn J. et al. Web-based survey of fertility issues in young women with breast cancer. J Clin Oncol 2004;22(20):4174–83.
15. Диникина Ю.В. Оптимизация методов сохранения фертильности у девочек с онкологической патологией. Диссертация на соискание ученой степени к.м.н. СПб.: [б.н.], 2011. 145 с. [Dinikina Yu.V. Optimization methods of fertility preservation for girls with cancer pathology. Dissertation for the degree of Ph.D. SPb.: [unnumbered], 2011. 145 p. (In Russ.)].
16. Peccatori F.A., Azim H.A. Jr, Orrecchia R. et al.; ESMO Guidelines Working Group. Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013;24 Suppl 6:vi160–70.
17. Sklar C.A., Mertens A.C., Mitby P. et al. Premature menopause in survivors of childhood cancer: a report from the childhood cancer survivor study. J Natl Cancer Inst 2006;98(13):890–6.
18. Ortin T., Shostak C., Donaldson S. Gonadal status and reproductive function following treatment for Hodgkin's disease in childhood: the Stanford experience. Int J Radiat Oncol Biol Phys 1990;19(4):873–80.
19. Beck-Fruchter R., Weiss A., Shalev E. GnRH agonist therapy as ovarian protectants in female patients undergoing chemotherapy: a review of the clinical data. Hum Reprod Update 2008;14(6):553–61.
20. Demeestere I., Brice P., Peccatori F. et al. Gonadotropin-releasing hormone agonist for the prevention of chemotherapy-induced ovarian failure in patients with lymphoma: 1-year follow-up of a prospective randomized trial. J Clin Oncol 2013;31(7):903–9.
21. Blumenfeld Z. How to preserve fertility in young women exposed to chemotherapy? The role of GnRH agonist cotreatment in addition to cryopreservation of embrya, oocytes, or ovaries. Oncologist 2007;12(9):1044–54.
22. Clowse M.E., Behera M.A., Anders C.K. et al. Ovarian preservation by GnRH agonists during chemotherapy: a meta-analysis. J Womens Health (Larchmt) 2009;18(3):311–9.
23. Chen H., Li J., Cui T., Hu L. Adjuvant gonadotropin-releasing hormone analogues for the prevention of chemotherapy induced premature ovarian failure in premenopausal women. Cochrane Database Syst Rev 2011;(11):CD008018.
24. Slater C.A., Liang M.H., McCune J.W. et al. Preserving ovarian function in patients receiving cyclophosphamide. Lupus 1999;8(1):3–10.
25. Ataya M., McKanna J., Weintraub A. et al. A luteinizing hormone-releasing hormone agonist for the prevention of chemotherapy-induced ovarian follicular loss in rats. Cancer Res 1985;45(8):3651–6.
26. Bokser L., Szende B., Schally A. Protective effects of D-Trp6-luteinising hormone-releasing hormone microcapsules against cyclophosphamide-induced gonadotoxicity in female rats. Br J Cancer 1990;61(6):861–5.
27. Ataya K., Ramahi-Ataya A. Reproductive performance of female rats treated with cyclophosphamide and/or LHRH agonist. Reprod Toxicol 1993;7(3):229–35.
28. Ataya K., Rao L.V., Lawrence E., Kimmel R. Luteinizing hormone-releasing hormone agonist inhibits cyclophosphamideinduced ovarian follicular depletion in rhesus monkeys. Biol Reprod 1995;52(2):365–72.
29. Imai A., Sugiyama M., Furui T. et al. Direct protection by gonadotropin-releasing hormone analog from doxorubicin-induced granulosa cell damage. Gynecol Obstet Invest 2007;63(2):102–6.
30. Letterie G.S. Anovulation in the prevention of cytotoxic-induced follicular attrition and ovarian failure. Hum Reprod 2004;19(4):831–7.
31. Blumenfeld Z. Gender difference: fertility preservation in young women but not in men exposed to gonadotoxic chemotherapy. Minerva Endocrinol 2007;32(1):23–34.
32. Lobo R.A. Potential options for preservation fertility in women. N Engl J Med 2005;353(1):64–73.
33. Oktay K., Sönmezer M., Oktem O. et al. Absence of conclusive evidence for the safety and efficacy of gonadotropin-releasing hormone analogue treatment in protecting against chemotherapy-induced gonadal injury. Oncologist 2007;12(9):1055–66.
34. Sönmezer M., Oktay K. Fertility preservation in female patients. Hum Reprod Update 2004;10(3):251–66.
35. Kitajima Y., Endo T., Nagasawa K. et al. Hyperstimulation and a gonadotropinreleasing
36. hormone agonist modulate ovarian vascular permeability by altering expression of the tight junction protein claudin-5. Endocrinology 2006;147(2):694–9.
37. Yu N., Chan C., Tang O. et al. Effect of pituitary downregulation on antral follicle count, ovarian volume and stromal blood flow measured by three-dimensional ultrasound with power Doppler prior to ovarian stimulation. Hum Reprod 2004;19(12):2811–5.
38. Blumenfeld Z. Gynecologic concerns for young women exposed to gonadotoxic chemotherapy. Curr Opin Obstet Gynecol 2003;15(5):359–70.
39. Janssens R., Brus L., Cahill D. et al. Direct ovarian effects and safety aspects of GnRH agonists and antagonists. Hum Reprod Update 2000;6(5):505–18.
40. Kolesnick R.N., Krönke M. Regulation of ceramide production and apoptosis. Annu Rev Physiol 1998;60:643–65.
41. Tilly J.L. Commuting the death sentence: how oocytes strive to survive. Nat Rev Mol Cell Biol 2001;2(11):838–48.
42. Johnson J., Canning J., Kaneko T. et al. Germline stem cells and follicular renewal in
43. the postnatal mammalian ovary. Nature 2004;428(6979):145–50.
44. Johansen J., Riis B., Hassager C. et al. The effect of a gonadotropin-releasing hormone agonist analog (nafarelin) on bone metabolism. J Clin Endocrinol Metab 1988;67(4):701–6.
45. Fogelman I. Gonadotropin-releasing hormone agonists and the skeleton. Fertil Steril 1992;57(4):715–24.
46. Scialli A., Jestila K., Simon J. Leuprolide acetate and bone mineral density measured by quantitive radiography. Fertil Steril 1993;59(3):674–6.
47. Qublan H., Amarin Z., Tahat Y. et al. Ovarian cyst formation following Gnrh agonist administration in IVF cycles: incidence and impact. Hum Reprod 2006;21(3):640–4.
48. von Wolff M., Kämmerer U., Kollmann Z. et al. Combination of gonadotropin-releasing hormone (GnRH) agonists with GnRH antagonists before chemotherapy reduce but does not
49. completely prevent a follicle-stimulating hormone flare-up. Fertil Steril 2011;95(1):452–4.
50. Blumenfeld Z., Avivi I., Eckman A. et al. Gonadotropin-releasing hormone agonist decreases chemotherapy-induced gonadotoxicity and premature ovarian failure in young female patients with Hodgkin lymphoma. Fertil Steril 2008;89(1):166–73.
51. Banzal A., Patel F., Rai B. et al. Gonadotrophin releasing hormone analogues for ovarian function preservation in young females undergoing chemotherapy. Asian Pac J Cancer Prev 2014;15(5):2185–90.
52. Somers E.C., Marder W., Christman G.M. et al. Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus. Arthritis Rheum 2005;52(9):2761–7.
53. Practice Committee of the American Society for Reproductive Medicine. Testing and interpreting measures of ovarian reserve: a committee opinion. Fertil Steril 2012;98(6):1407–15.
Рецензия
Для цитирования:
Белогурова М.Б., Диникина Ю.В., Лисянская А.С., Тапильская Н.И., Радулеску Г.Г., Викторович Т.Д., Шац Л.И., Чавпецова Э.Д. Возможности применения аналогов гонадотропин-рилизинг гормона у девочек пубертатного возраста с онкологическими заболеваниями. Российский журнал детской гематологии и онкологии (РЖДГиО). 2015;2(4):34-41. https://doi.org/10.17650/2311-1267-2015-2-4-34-41
For citation:
Belogurova M.B., Dinikina Yu.V., Lisyanskaya A.S., Tapilskaya N.I., Radulesku G.G., Viktorovich T.D., Shats L.I., Chavpetsova E.D. Possible applications analogues of gonadotropin-releasing hormone puberty in girls with cancer. Russian Journal of Pediatric Hematology and Oncology. 2015;2(4):34-41. (In Russ.) https://doi.org/10.17650/2311-1267-2015-2-4-34-41
Просмотров: 624
Послать статью по эл. почте 